Founding and Development
(1995-2003)
Aikorn Biotechnology (Hangzhou) Co., Ltd. has become a professional manufacturer of rapid diagnostic series from its foundation to the completion of the construction of rapid immunoassay technology platform.
Aikon's global development strategy requires us to have a perfect quality management system to continuously improve our international competitiveness and ensure the company's continuous and rapid development. After obtaining FDA factory registration in 1998 and GMP certification in 1999, Akcome has gradually formed an enterprise competitive advantage with quality as its core competitiveness by virtue of its perfect quality management system and excellent product quality. Independent research and development, create brand
(2004-2008)
Aikon takes independent innovation as the main theme, increases the investment in technology research and development, integrates the latest technology in BT and IT fields, and continuously innovates and develops in molecular biology diagnostic reagents, biosensing instruments, bioelectronics and other high-precision fields, to seize the high point of the bio-industry and become the leading company of rapid diagnostics and bioelectronics. We will continue to innovate and develop in the high-tech fields such as molecular biology diagnostic reagents, biosensing instruments and bio-electronics, seize the high ground in the bio-industry, and become an industry leader in the rapid diagnostic and medical device segment.
Research and development and technological innovation are the source power of enterprise development, and the cross-development of biology and information technology will be the inevitable trend of future technological development. Akcome has invested a large number of R&D personnel and R&D funds to complete the construction of four major technology platforms, including rapid immunoassay technology platform, antigen-antibody technology platform, biosensor technology platform, and rapid gene diagnostic technology platform, and has successfully developed a number of medical device products with independent intellectual property rights, such as monoclonal antibody diagnostic reagents, blood glucose testing systems, and urinalysis systems.
Aikon people know that quality is the lifeline of success. With perfect quality management system and excellent product quality, Aikon passed the FDA on-site audit for the first time in 2005, and passed the FDA on-site audit again in 2008 with the excellent result of "zero defect item". The quality of our products meets the standards of the State Food and Drug Administration, European CE registration, and the U.S. Food and Drug Administration's 510K product certification standards.
After years of brand building, Akcome has formed a set of perfect quality management system for product development, manufacturing, sales and service, and several products have the first domestic market share. Through the continuous and effective implementation, operation and maintenance of the quality management system, Akcome strictly controls all aspects from product design and development to product delivery, from raw material procurement to after-sales service, etc. to provide customers with more satisfactory products and services. Technological Innovation, Leading in Science and Technology
(2008-present)
Relying on the advantages of talents and technology in China and the United States, Akcome has formed a perfect industrialized system of research and development, production and sales in the field of biological diagnosis, and has become a supplier of products and services in the field of global health.
Following the successful development of the Acme series of blood glucose meters, urine analyzers and other products, Akcome has launched dry biochemistry analyzers, hemoglobin analyzers, lipid analyzers and other medical devices and corresponding test reagents, more than 20 kinds of PCR test reagents, ELISA reagents, colloidal gold test reagents and other diagnostic products on the market every year, the products are well sold in more than 140 countries and regions in the world. The company has become one of the world's largest industrialization bases for biological diagnostic products.